Audentes Therapeutics, Inc.

( )
BOLD After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 0.80%63.941.0%$481.30m
AMGNAmgen, Inc. -0.72%235.041.3%$433.22m
BIIBBiogen, Inc. -1.35%284.211.4%$384.69m
ILMNIllumina, Inc. -1.21%327.003.5%$329.26m
VRTXVertex Pharmaceuticals, Inc. -0.30%233.911.9%$282.39m
REGNRegeneron Pharmaceuticals, Inc. -0.71%356.602.6%$239.03m
EXASEXACT Sciences Corp. -2.93%92.1824.0%$232.61m
ALXNAlexion Pharmaceuticals, Inc. -2.56%108.552.0%$173.61m
INCYIncyte Corp. -0.31%78.242.5%$131.13m
AAgilent Technologies, Inc. -1.23%89.021.6%$127.01m
SRPTSarepta Therapeutics, Inc. -3.93%113.6814.6%$110.30m
BMRNBioMarin Pharmaceutical, Inc. -2.24%85.634.3%$107.80m
SGENSeattle Genetics, Inc. 3.27%115.356.1%$99.56m
BLUEbluebird bio, Inc. -4.35%89.7214.2%$89.98m
DERMDermira, Inc. -0.37%18.763.8%$83.55m

Company Profile

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.